Business Description
Merck & Co Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
MRK.USA0QAH.UKMRCK34.Brazil6MK.GermanyMRK.MexicoMRK.ArgentinaMRK.Peru1MRKX.ItalyMRK.AustriaMRK.FranceMRK.ChileMRK.RomaniaMRK.UkraineMRK.Switzerland IPO Date
2023-03-13Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.85 | |||||
| Debt-to-EBITDA | 2.83 | |||||
| Interest Coverage | 7.61 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.08 | |||||
| Beneish M-Score | -2.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.4 | |||||
| 3-Year EBITDA Growth Rate | 23.9 | |||||
| 3-Year EPS without NRI Growth Rate | 26.1 | |||||
| 3-Year FCF Growth Rate | 14 | |||||
| 3-Year Book Growth Rate | 21.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 14.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 4.27 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 96.24 | |||||
| 9-Day RSI | 82.54 | |||||
| 14-Day RSI | 69.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.38 | |||||
| Quick Ratio | 1.12 | |||||
| Cash Ratio | 0.38 | |||||
| Days Inventory | 133.57 | |||||
| Days Sales Outstanding | 62.49 | |||||
| Days Payable | 82.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.07 | |||||
| Dividend Payout Ratio | 1.22 | |||||
| 3-Year Dividend Growth Rate | 7.4 | |||||
| Forward Dividend Yield % | 2.88 | |||||
| 5-Year Yield-on-Cost % | 3.14 | |||||
| Shareholder Yield % | 2.95 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.87 | |||||
| Operating Margin % | 13.75 | |||||
| Net Margin % | 7.77 | |||||
| FCF Margin % | 22.23 | |||||
| ROE % | 10.61 | |||||
| ROA % | 4.3 | |||||
| ROIC % | 6.64 | |||||
| ROC (Joel Greenblatt) % | 36.59 | |||||
| ROCE % | 10.18 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 57.64 | |||||
| Forward PE Ratio | 12.15 | |||||
| PE Ratio without NRI | 33.58 | |||||
| Shiller PE Ratio | 29.98 | |||||
| Price-to-Owner-Earnings | 219.34 | |||||
| PEG Ratio | 2.71 | |||||
| PS Ratio | 4.45 | |||||
| PB Ratio | 6.38 | |||||
| Price-to-Tangible-Book | 305.31 | |||||
| Price-to-Free-Cash-Flow | 20.05 | |||||
| Price-to-Operating-Cash-Flow | 15.36 | |||||
| EV-to-EBIT | 33.92 | |||||
| EV-to-Forward-EBIT | 11.12 | |||||
| EV-to-EBITDA | 23.46 | |||||
| EV-to-Forward-EBITDA | 9.77 | |||||
| EV-to-Revenue | 4.87 | |||||
| EV-to-Forward-Revenue | 4.58 | |||||
| EV-to-FCF | 21.95 | |||||
| Price-to-Projected-FCF | 1.88 | |||||
| Price-to-Median-PS-Value | 1.05 | |||||
| Price-to-Peter-Lynch-Fair-Value | 6.01 | |||||
| Price-to-Graham-Number | 21.29 | |||||
| Earnings Yield (Greenblatt) % | 2.95 | |||||
| FCF Yield % | 5.01 | |||||
| Forward Rate of Return (Yacktman) % | 9.54 |
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Merck & Co Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 55,420.077 | ||
| EPS (TTM) (€) | 1.725 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 69.74 | ||
| 14-Day ATR (€) | 0.443382 | ||
| 20-Day SMA (€) | 94.05 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 92.8 - 101.6 | ||
| Shares Outstanding (Mil) | 2,534.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merck & Co Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Merck & Co Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Merck & Co Inc Frequently Asked Questions
What is Merck & Co Inc(CHIX:6MKd)'s stock price today?
The current price of CHIX:6MKd is €97.70. The 52 week high of CHIX:6MKd is €101.60 and 52 week low is €92.80.
When is next earnings date of Merck & Co Inc(CHIX:6MKd)?
The next earnings date of Merck & Co Inc(CHIX:6MKd) is 2024-02-02 Est..
Does Merck & Co Inc(CHIX:6MKd) pay dividends? If so, how much?
The Dividend Yield %  of Merck & Co Inc(CHIX:6MKd) is 2.07% (As of Today), Highest Dividend Payout Ratio of Merck & Co Inc(CHIX:6MKd) was 1.22. The lowest was 0.37. And the median was 0.49. The  Forward Dividend Yield % of Merck & Co Inc(CHIX:6MKd) is 2.88%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers